newsfilter
← Latest News
PR Newswire·

Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update

NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this yearDraft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous